CANSINOBIO (06185): DTcP-Hib-MCV4 combination vaccine approved for clinical trials in China.

CANSINOBIO(06185) announcement that the company's developed adsorbed cell-free combination of tetanus (component) diptheria (DTcP) B-type influenza Haemophilus influenzae type b (Hib) -ACYW135 group meningococcal conjugate (MCV4) vaccine (DTcPHib-MCV4 combination vaccine) has been approved by the China National Medical Products Administration to conduct related clinical trials. As of the date of this announcement, the company's domestic first meningococcal quadrivalent conjugate vaccine product Manhaisin has obtained a drug registration certificate and has been commercialized as part of the DTcP-Hib-MCV4 combination vaccine, the infant and young child DTcP is in Phase III clinical stage, and the Hib vaccine is in Phase I clinical stage. Based on the accumulated data in the development of the above-mentioned vaccines, the company plans to develop DTcP-Hib-MCV4 combination vaccine to meet the market demand for multi-vaccines and to form differentiated competition.